In conclusion, Anak and BM-MSC therapy are two novel therapeutic approaches that clearly improved the inflammatory responses in DCM by suppressing TNFα/ILlβ/caspase 1, macrophage, and CD8 T-cell. This evidence concerns the gene CD8A and familial dilated cardiomyopathy.